FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $577.95M | ||||
Company |
Location |
Date |
Amt. (M) |
Details |
Ablynx NV |
Ghent, Belgium | 8/23/06 |
€40 ($51) |
The Series C financing was led by KBC and included SR One, as well as existing investors Abingworth Management, Alta Partners, Biotech Fund Flanders, Gilde Healthcare Partners, GIMV, Sofinnova Partners and VIB |
Acceleron |
Cambridge, Mass. |
8/2/06 |
$30 |
The Series B financing round was led by new investor OrbiMed Advisors and included existing investors Advanced Technology Ventures, Flagship Ventures, Polaris Ventures, Sutter Hill Ventures and Venrock Associates |
Accera Inc. |
Broomfield, Colo. |
8/16/06 |
$7.5 |
Inventages Venture Capital SA led the Series B financing, which included Posco BioVentures and private investors |
Arisaph Pharmaceuticals |
Boston |
8/9/06 |
$16 |
Kos Pharmaceuticals Inc. and 2004 Oikos Investment Partners LP provided $8M in the second closing of a milestone-driven $16M financing round |
Atlas |
Stockholm, Sweden |
8/22/06 |
ND |
Investor Growth Capital and Scandinavian Life Science Venture invested in the seed round; other owners are a consortium of 54 scientists, and the institutions KTH and Uppsala University |
BioAssets |
Natick, Mass. |
8/24/06 |
$0.8 |
The seed financing was provided by an institutional investor and orthopedic spine surgeons |
Biodel Inc. |
Danbury, Conn. |
8/2/06 |
$21 |
The Series B financing was led by Great Point Partners, OrbiMed Advisors and Vivo Ventures |
Cabrellis |
San Diego |
8/7/06 |
$27.5 |
Investing in the Series A financing were Domain Associates, Forward Ventures, Lilly Ventures, Novo A/S, ProQuest Investments, RBC Capital Partners, RiverVest Venture Partners and S.R. One Ltd. |
Cempra |
Research Triangle Park, N.C. |
8/16/06 |
$14 |
Lead investors in the Series A financing round were Intersouth Partners and investment banker I. Wistar Morris III |
ChemoCentryx |
Mountain View, Calif. |
8/24/06 |
$17.7 |
Participating in the Series C financing were Jennison Associates, HBM BioVentures, OrbiMed Advisors, Techne Corp. Alta Partners and GIMV; total does not include an undisclosed Series D investment provided by new partner GlaxoSmith-Kline plc, which was disclosed concurrently |
Codexis Inc. |
Redwood City, Calif. |
8/24/06 |
$37 |
The Series D financing was led by Bio*One Capital Pte. Ltd., and included existing investors CMEA Ventures, Pequot Ventures, Chevron Technology Ventures and Maxygen Inc. |
Elara |
Heidelberg, Germany |
8/9/06 |
ND |
EMBL Ventures GmbH provided seed funding to the company, a spinout of the European Molecular Biology Laboratory |
ESBATech AG |
Zurich, Switzerland |
8/2/06 |
$41 |
The Series B financing round was led by new investors SV Life Sciences, Clarus Ventures, HBM BioVentures and HBM BioCapital; Series A investors Novartis Venture Fund, BioMedinvest and VI Partners also participated |
4-Antibody AG |
Basel, Switzerland |
8/21/06 |
CHF6 ($4.9) |
The Series A financing was provided by existing investors, including Biomedinvest AG, Grazia Equity, Life Science Partners and Mulligan Biocapital |
Intranasal |
Lexington, Ky. |
8/15/06 |
$39.1 |
SV Life Sciences led the Series A financing, which included Burrill & Co., Tullisickerson, Fidelity Biosciences, ApjohnVentures, Fort Washington Capital, Commonwealth Seed Capital and Kentucky Co-Investment Partners LP |
Kemia Inc. |
San Diego |
8/23/06 |
$31 |
Aberdare Ventures led the Series C financing, which included other new investors MedImmune Ventures Inc. and Red Abbey Venture Partners, and existing investors Alta Partners, Forward Ventures, Hamilton Bioventures, JPMorgan Partners, Novartis Bioventures, Novo A/S and Texas Pacific Group |
LipoScience |
Raleigh, N.C. |
8/15/06 |
$13 |
Investors in the Series F financing included Camden Partners LLC, GE Capital Equity Investments, Inveco Private Capital, Pappas Ventures, Sightline Partners, Three Arch Partners and Varian Inc. |
Logical |
Pittsburgh |
8/10/06 |
ND |
The seed funding round was provided by PA Early Stage Partners |
Magen |
Cambridge, Mass. |
8/28/06 |
$15.4 |
The Series A financing was led by Highland Capital Partners and included new investors IDG Ventures and QVT Financial LP, and previous investors Alexandria Real Estate, ARCH Venture Partners, Lux Capital, TVM Capital and Venrock Associates |
MerLion |
Singapore |
8/21/06 |
$30 |
The financing round was led by Aravis Venture and Bio*One Capital Pte. Ltd., and included Nomura Research and Advisory, Aurelia Private Equity, Brandenburg Capital, Bioveda Capital, Novartis Venture Fund, Mitsubishi Corp. and 3i Group Investment LP |
Microchip |
Dublin, Calif. |
8/29/06 |
$4.5 |
The $4.5M Series A round includes milestone- driven components; the round was co-led by In-Q-Tel and RONA Syndicates LLC |
NanoBio |
Ann Arbor, Mich. |
8/7/06 |
$10 |
Perseus LLC provided $10M of what could be a $30M investment; two more $10M tranches are contingent on attaining certain milestones |
National Stem |
New York |
8/21/06 |
ND |
The undisclosed financing was completed as the company was nearing completion of a reverse merger with a public company |
Peakadilly |
Ghent, Belgium |
8/22/06 |
€8.5 ($10.6) |
Investors in the second close of the Series A financing were GIMV, Life Science Partners, KBC Private Equity and Baekeland Fonds II; the first part of the $18.4M round closed in April; Life Science Partners led the complete round |
Protalix |
Carmiel, Israel |
8/22/06 |
$15 |
Philip Frost, the controlling shareholder of Orthodontix Inc., led the investment, gaining 14% of Protalix, which is acquiring Orthodontix in a reverse merger |
Reata |
Dallas |
8/4/06 |
$22.6 |
The financing round was led by Cardinal Investment Co.; new investor Novo A/S also participated |
Taligen |
Aurora, Colo. |
8/2/06 |
$3.75 |
Taligen met the development milestone needed to trigger the second tranche of its Series A financing round, which totaled $3.75M; it was led by Sanderling Ventures, and included Tango and High Country Venture and the University of Colorado |
Thiakis Ltd. |
London |
8/21/06 |
£10 ($19) |
The Series A financing was led by Novo A/S and Advent Venture Partners, and included Imperial Innovations, The Royal Society, Esperante, Consensus Business Group and NPI Ventures |
TolerRx Inc. |
Cambridge, Mass. |
8/16/06 |
$35.6 |
FrontPoint Partners LLC led the financing round, which included other new investors Mesirow Financial, Swiss Re, QVT Fund LP, IBT Management Corp., Brookstone Capital and the Juvenile Diabetes Research Foundation, and existing investors Skyline Ventures, Bear Stearns, Sprout Group, Rho Ventures, Artal Services NV and HealthCare Ventures |
Zogenix Inc. |
San Diego |
8/28/06 |
$60 |
The Series A financing was co-led by Clarus Ventures and Domain Associates LLC, and included BA Venture Partners; Thomas, McNerney & Partners; and Life Science Angels Inc. |
Notes: | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
ND = Not disclosed. | ||||
To read more on related topics, click on one of the words below.